|Bid||0.00 x 0|
|Ask||359.70 x 0|
|Day's Range||355.75 - 361.80|
|52 Week Range||271.15 - 367.00|
|Beta (3Y Monthly)||1.28|
|PE Ratio (TTM)||22.99|
|Forward Dividend & Yield||8.15 (2.31%)|
|1y Target Est||326.96|
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 21 October 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with.
Paul Hudson is examining the organization from top to bottom with the goal of developing a strategy to put the company on the road to success Continue reading...
Is Novo Nordisk A/S (NYSE:NVO) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
Does the October share price for Novo Nordisk A/S (CPH:NOVO B) reflect what it's really worth? Today, we will estimate...
Cool chain partners are changing their mindsets to join shippers and start-ups shaping the supply chain of the future, according to speakers at the recent Cool Chain Association's (CCA) pharma and biosciences conference in Paris. Conference delegates also heard that the air cargo industry could make a difference in final mile delivery that could save the lives of infants. The CCA, which hosts two regular events each year, one on pharma and one on perishables, brings together industry leaders from across the cool chain to network.
Novo Nordisk's newest diabetes treatment, an oral drug called Rybelsus, won't immediately gouge another medicine from pharmaceutical company Eli Lilly. Both are GLP-1 receptor agonists.
Danish drugmaker Novo Nordisk is aiming for a big slice of the multibillion-dollar diabetes market with a new pill, approved by U.S. authorities on Friday, that caters for patients with an aversion to needles. The company built its position as the world's biggest insulin maker on the back of injectable drugs, but now aims to transform the market with a first-of-its-kind tablet version of its semaglutide drug. While more than 70% of diabetes prescriptions in the United States are already for oral treatments, none of these are from the GLP-1 class that Novo specialises in, and which are viewed as highly effective medicines that stimulate insulin production.
The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker which hopes to transform the market by offering patients a non-injectable treatment. The world's biggest producer of diabetes drugs already sells an injectable once-weekly version of semaglutide under the brand name Ozempic at nearly $800 per month. Novo did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be "competitively priced" with other drugs in the same "GLP-1" class of medicines.
Bagsværd, Denmark, 20 September 2019 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide tablets), as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Rybelsus®, the brand name for oral semaglutide in the US, is the first approved glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet. The approval of Rybelsus® is based on the results from 10 PIONEER clinical trials which included 9,543 adults with type 2 diabetes.
European stocks clocked their fifth straight week of gains on Friday with investors buying into the oil and gas and banking sectors, and Novo Nordisk rising after U.S. approval of its oral diabetes drug. Investors also sought refuge in the so-called defensive sectors such as utilities, real-estate and food and beverages ahead of a week packed with economic data. The United Nations (UN) general assembly will also provide clues on the fallout from attacks on Saudi oil facilities last weekend and indications of a potential meeting between the presidents of Iran and the United States.
Novo Nordisk stock popped Tuesday after an analyst suggested the pharmaceutical company's oral diabetes treatment, semaglutide, could swipe share from Eli Lilly's rival drug, Trulicity.
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.
Her daily routine is a matter of life and death for Georgina. She is one of Britain's one million diabetics now facing the possibility of medical shortages if the UK plunges out of the European Union without a deal at the end of October. (SOUNDBITE) (English) LONDON RESIDENT AND DIABETES PATIENT, GEORGINA, SAYING: "I can't tell you how worried I am about that. It's life-threatening for me." Her fears have been exacerbated by the British government's own planning for a worst case scenario. The Yellowhammer document suggests the important Calais to Dover trade route could face months of disruption, and the pharmaceuticals industry is particularly vulnerable. That's because three quarters of the 37 million packs of drugs imported from Europe each month, come through the short straits route. Georgina is concerned that the medical supplies she depends on could dwindle. She tests her blood sugar levels four times a day to work out how much of an insulin boost she needs at meal times, in addition to a pump that gives her a low level dosage of insulin 24 hours a day. (SOUNDBITE) (English) LONDON RESIDENT AND DIABETES PATIENT, GEORGINA, SAYING: "I can live without the pump and I can live without all the bits and pieces that go with the pump but I cannot live without the blood testing strips because that's just as important, nearly as important, as having an adequate insulin supply. And the two really go so hand in hand, that's the one thing I don't think people realize." She may take some comfort from private sector preparations. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "At Novo Nordisk we've been preparing for the last three years, if not more than that, for the worst-case scenario." Pinder Sahota is the UK general manager of the world's biggest insulin maker, Novo Nordisk. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "So what we've done is we've increased our stock level from - a normal average of stock-holding is six weeks, we've increased that to 18 weeks." That's a warehouse capacity of 3.8 million packs of insulin. Piled up - they'd stand 12 times the height of London's Shard skyscraper. Novo Nordisk has also reserved spaces on alternate ferry routes and air freight if required while exploring other factors such as what to do in the event of fuel shortages. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "Whilst we can control what we can control, it's the uncertainties of how long will the delays be, that are factors outside our control. But we're doing everything we can to ensure that the patients can continue to get the medicines that they need." But the situation is increasing tensions between industry and the government - and not just around the intricacies of planning for a no-deal. Hugo Fry, UK managing director of France's Sanofi, also says that patients have to be prioritized. (SOUNDBITE) (English) MANAGING DIRECTOR OF SANOFI UK, HUGO FRY, SAYING: "Of course, we're starting to ask ourselves the question... although we're happy to do it, it is starting to weigh on our balance sheet, on our logistics, keeping all this additional stock in the country." And that leads to another frustration - that while the companies like Sanofi and Novo Nordisk dedicate huge resources to such preparation, they are having to spend less time on their normal job - bringing innovative drugs to market.